References
Anonymous (2015). Patient Perspectives: What is Vitiligo? Pediatr
Dermatol 32: e328-329.
Boniface K, Seneschal J, Picardo M, & Taieb A (2018). Vitiligo: Focus
on Clinical Aspects, Immunopathogenesis, and Therapy. Clin Rev Allergy
Immunol 54: 52-67
Boisseau-Garsaud AM, Garsaud P, Cales-Quist D, Helenon R, Queneherve C,
& Claire RC (2000). Epidemiology of vitiligo in the French West Indies
(Isle of Martinique). Int J Dermatol 39: 18-20.
Curtis, M J, Alexander, S, Cirino, G, Docherty, J R, George, C H,
Giembycz, M A, & Ahluwalia, A. (2018). Experimental design and analysis
and their reporting II: Updated and simplified guidance for authors and
peer reviewers. British Journal of Pharmacology, 175: 987-993.
Cohen BE, Elbuluk N, Mu EW, & Orlow SJ (2015). Alternative Systemic
Treatments for Vitiligo: A Review. Am J Clin Dermatol 16: 463-474.
Clevers H, & Nusse R (2012). Wnt/β-catenin signaling and disease. Cell
(Cambridge, MA, U S) 149: 1192-1205.
Chen D, Zhang H, Jing C, He X, Yang B, Cai J, et al . (2018).
Efficient synthesis of new phenanthridine Wnt/β-catenin signaling
pathway agonists. Eur J Med Chem 157: 1491-1499.
Chen D-z, Yang B-j, He X-l, Fan S-r, Cai J-y, Jing C-x, et al .
(2019). Design, synthesis and structure-activity relationship
optimization of phenanthridine derivatives as new Wnt/β-catenin
signalling pathway agonists. Bioorg Chem 84: 285-294.
Chen D-Z, Jing C-X, Cai J-Y, Wu J-B, Wang S, Yin J-L, et al .
(2016). Design, Synthesis, and Structural Optimization of
Lycorine-Derived Phenanthridine Derivatives as Wnt/β-Catenin Signaling
Pathway Agonists. J Nat Prod 79: 180-188.
Ezzedine K, Eleftheriadou V, Whitton M, & van GN (2015). Vitiligo.
Lancet 386: 74-84.
Ezzedine K, Lim HW, Suzuki T, Katayama I, Hamzavi I, Lan CCE, et
al . (2012). Revised classification/nomenclature of vitiligo and related
issues: the Vitiligo Global Issues Consensus Conference. Pigment Cell
Melanoma Res 25: E1-13.
Elbuluk N, & Ezzedine K (2017). Quality of Life, Burden of Disease,
Co-morbidities, and Systemic Effects in Vitiligo Patients. Dermatol Clin
35: 117-128.
Hayashi M, Jin Y, Ferrara TM, Spritz RA, Yorgov D, Santorico SA,et al . (2016). Autoimmune vitiligo is associated with
gain-of-function by a transcriptional regulator that elevates expression
of HLA-A*02:01 in vivo. Proc Natl Acad Sci U S A 113: 1357-1362.
Hoverter NP, & Waterman ML (2008). A Wnt-fall for gene regulation:
repression. Sci Signaling 1.
Huang S-MA, Mishina YM, Liu S, Cheung A, Stegmeier F, Michaud GA,et al . (2009). Tankyrase inhibition stabilizes axin and
antagonizes Wnt signalling. Nature (London, U K) 461: 614-620.
Lopes C, Trevisani VFM, Trevisani VFM, Trevisani VFM, Melnik T, &
Melnik T (2016). Efficacy and Safety of 308-nm Monochromatic Excimer
Lamp Versus Other Phototherapy Devices for Vitiligo: A Systematic Review
with Meta-Analysis. Am J Clin Dermatol 17: 23-32.
Li L, Liang Y, Zhang D, Wang C, Pan N, Hong J, et al . (2019). The
308-nm excimer laser stimulates melanogenesis via the wnt/β-Catenin
signaling pathway in B16 cells. J Dermatol Treat 30: 826-830.
Lerner AB, Denton CR, & Fitzpatrick TB (1953). Clinical and
experimental studies with 8-methoxypsoralen in vitiligo. J Invest
Dermatol 20: 299-314.
Liu L-P, Li Y-M, Guo N-N, Li S, Ma X, Zhang Y-X, et al . (2019).
Therapeutic Potential of Patient iPSC-Derived iMelanocytes in Autologous
Transplantation. Cell Rep 27: 455-466.e455.
Manga P, Sheyn D, Yang F, Sarangarajan R, & Boissy RE (2006). A role of
tyrosinase-related protein 1 in 4-tert-butylphenol-induced toxicity in
melanocytes: implication for vitiligo. Am J Pathol 169: 1652-1662.
Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS,et al . (2009). AutoDock4 and AutoDockTools4: Automated docking
with selective receptor flexibility. J Comput Chem 30: 2785-2791.
Niezgoda A, Nowowiejska L, Bialecka A, Mecinska-Jundzill K, Adamska U,
Czajkowski R, et al . (2017). Properties of skin stem cells and
their potential clinical applications in modern dermatology. Eur J
Dermatol 27: 227-236.
Olsen JR, Gallacher J, Finlay AY, Piguet V, & Francis NA (2016).
Quality of life impact of childhood skin conditions measured using the
Children’s Dermatology Life Quality Index (CDLQI): a meta-analysis. Br J
Dermatol 174: 853-861.
Picardo M, Dell’Anna ML, Ezzedine K, Taieb A, Hamzavi I, Harris JE,et al . (2015). Vitiligo. Nat Rev Dis Primers 1: 15011.
Rashighi M, & Harris JE (2017). Vitiligo Pathogenesis and Emerging
Treatments. Dermatol Clin 35: 257-265.
Rodrigues M, Ezzedine K, Hamzavi I, Pandya AG, & Harris JE (2017).
Current and emerging treatments for vitiligo. J Am Acad Dermatol 77:
17-29.
Sehgal VN, & Srivastava G (2007). Vitiligo: compendium of
clinico-epidemiological features. Indian J Dermatol Venereol Leprol 73:
149-156.
Schwarz-Romond T, Fiedler M, Shibata N, Butler PJG, Kikuchi A, Higuchi
Y, et al . (2007). The DIX domain of Dishevelled confers Wnt
signaling by dynamic polymerization. Nat Struct Mol Biol 14: 484-492.
Wang S, Yin J, Chen D, Nie F, Song X, Fei C, et al . (2013).
Small-molecule modulation of Wnt signaling via modulating the
Axin-LRP5/6 interaction. Nat Chem Biol 9: 579-585.
Wang JY, Chen H, Wang YY, Wang XQ, Chen HY, Zhang M, et al .
(2017). Network pharmacological mechanisms of Vernonia anthelmintica
(L.) in the treatment of vitiligo: isorhamnetin induction of
melanogenesis via up-regulation of melanin-biosynthetic genes. BMC Syst
Biol 11: 103/101-103/112.
Yamada T, Hasegawa S, Inoue Y, Date Y, Yamamoto N, Mizutani H, et
al . (2013). Wnt/β-Catenin and Kit Signaling Sequentially Regulate
Melanocyte Stem Cell Differentiation in UVB-Induced Epidermal
Pigmentation. J Invest Dermatol 133: 2753-2762.
Zeng X, Tamai K, Doble B, Li S, Huang H, Habas R, et al . (2005).
A dual-kinase mechanism for Wnt co-receptor phosphorylation and
activation. Nature (London, U K) 438: 873-877.
Zimmerman ZF, Moon RT, & Chien AJ (2012). Targeting Wnt pathways in
disease. Cold Spring Harbor Perspect Biol 4:
a008086/008081-a008086/008024.